Tetraphase Pharmaceuticals, Inc. announced Tuesday that the IGNITE2 phase 3 clinical trial of eravacycline administered as an IV to oral transition therapy for the treatment of complicated urinary tract infections failed to meet its primary endpoint of statistical non-inferiority compared to levofloxacin. Read More »

Tim Wentworth, the company's current president, will take the helm in May 2016. Read More »

The Association of Clinical Research Organizations is launching its second CRO Innovation Month with the theme of "Transforming Patient Centered Drug Development." Read More »

RedHill Biopharma Ltd. announced Tuesday additional supportive data from the first Phase III study with RHB-105 for eradication of H. pylori. Read More »

Immunicum AB recently signed a research agreement with Rutgers Cancer Institute of New Jersey to supply the institution with the company's adenovirus (Ad5PTDf35) technology. Read More »

Company to begin Phase IIb clinical trial of IFNa-Kinoid in Systematic Lupus Erythematosus Read More »

Villa Medical Clinic in Newburg, Oregon, recently chose Allscripts Chronic Care Management (CCM) Program to start ongoing monthly outreach to hundreds of patients who suffer from two or more chronic conditions without adding staff or increasing employee workloads. Read More »

AstraZeneca said Sept. 3 that the U.S. Food and Drug Administration has approved Brilinta (ticagrelor) tablets at a new 60 mg dose to be used in patients with a history of heart attack after the first year. Read More »

Cynapsus Therapeutics Inc. on Wednesday announced enrollment of the first patient in the CTH-301 clinical trial. Read More »

Supernus Pharmaceuticals Inc. on Tuesday received its fifth patent covering Oxtellar XR, its novel once-daily, extended-release oxcarbazepine product. Read More »

Innocoll AG on Wednesday announced the first patient has been dosed in its MATRIX-1 (Multisite Assessment of Postoperative Pain Reduction wIth XaraColl) Phase 3 study for the treatment of postoperative pain after open hernioplasty with mesh using XaraColl. Read More »

Heat Biologics Inc. on Tuesday announced it enrolled the first patient in a Phase 1b clinical trial that examines the combination of its HS-110 therapeutic vaccine and the Bristol-Myers Squibb PD-1 inhibitor nivolumab (Opdivo) in non-small cell lung cancer. Read More »

XBiotech, a developer of True Human therapeutic antibodies, announced Tuesday the completion of the first cohort in its Phase 1 of 2 for a clinical study of a novel True Human monoclonal antibody therapy to treat all forms of Staphylococcus aureus infections. Read More »

Adaptimmune Therapeutics, PLC announced Tuesday that the first patient has been dosed in its expanded Phase I/II trial of its affinity enhanced T-cell receptor therapeutic that targets the NY-ESO-1 cancer antigen in synovial sarcoma patients. Read More »

Merck on Wednesday announced that the U.S. Food and Drug Administration has approved a supplemental New Drug Application for EMEND (aprepitant) capsules, a substance P/neurokinin 1 receptor antagonist. Read More »

Evotec AG on Wednesday announced that CHDI Foundation Inc. has extended and expanded its collaboration with Evotec through August 2018. Read More »

OncoMed Pharmaceuticals Inc. on Monday announced it has completed patient enrollment in its Phase 2 ALPINE clinical trial of tarextumab for the treatment of pancreatic cancer. Read More »

BeyondSpring Pharmaceuticals Inc., a clinical stage biopharmaceutical company, announced Monday its lead compound, Plinabulin, will be presented in two posters at the upcoming 16th World Conference on Lung Cancer (WCLC) in Denver. Read More »

Agile Therapeutics Inc., a women's health specialty pharmaceutical company, on Monday announced active recruitment has closed in its ongoing single-arm, open-label Phase 3 SECURE clinical trial of Twirla, its investigational contraceptive patch. Read More »

Corbus Pharmaceuticals Holdings Inc. on Monday announced that patient enrollment has commenced in the Phase 2 clinical study of its investigational new drug, Resunab, designed for the treatment of diffuse cutaneous systemic sclerosis. Read More »